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1. Introduction 
 Protein mimics form a category of medium sized molecules, 
which might have a large impact because they could become 
viable medium-sized molecule alternatives of biologics such as 
antibodies and vaccines. Thus, they may have advantages closer 
to those of smaller molecules such as better bio-availability and 
stability and be less immunogenic. We have provided bases for 
realization of molecular construction of protein mimics by (1) the 
development of syntheses of different scaffolds for attachment of 
(cyclic) peptides,1-4 (2) synthetic approaches for attachment of 
different (cyclic) peptides to scaffolds,5-10 and (3) the generation 
of collections of the resulting protein mimics.9,11,12 The latter 
aspect is especially note worthy since design of an optimal 
protein mimic is often hardly possible even when a significant 
amount of structural data is available, so there has to be a 
versatile approach to prepare collections or libraries of protein 
mimics, which can be screened to find protein mimic "hits"9,12 
For this purpose a non-orthogonally protected scaffold is used, 
providing direct access to the required unprotected protein 
mimics, which can be screened as mixtures or as single 
compounds, followed by MS-identification of the hit(s).11,12 
However, this/these hit(s) then have to be re-synthesized using 
the an orthogonally protected scaffold to obtain appreciable 
quantities of single protein mimic compounds for validation of 
the hit and subsequent structural and biological activity studies 
Thus, a scalable (re)synthesis approach for any individual hit is 
absolutely essential. So far, we have developed semi-
orthogonally protected TAC, ATAC and TACO scaffolds,1,3,4  
 
Figure 1.  Orthogonally protected TAC1,3,13,14, ATAC3, and TACO4 scaffolds 
 
which can be applied for the convenient synthesis of selected 
protein mimics (Figure 1). Other important orthogonally 
protected molecular scaffolds include the RAFT-peptide (Mutter 
and co-workers15), cholic acid derivatives (Savage and co-
workers16), cyclic β-peptide and penta-erythrityltetramine 
derivatives (Lönnberg and co-workers17,18), a pentaerythritol 
derivative (De Clerq and co-workers19) as well as a cyclicpeptide 
derivative by Eichler and co-workers.20 
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The synthesis of a (semi)orthogonally protected CycloTriVeratrilene (CTV) scaffold derivative 
as well as the sequential introduction of three different peptide loops onto this molecular 
scaffold via Cu(I)-catalyzed azide alkyne cycloaddition towards a medium-sized protein mimic 
is described. This approach for the construction of medium-sized protein mimics is illustrated by 
the synthesis of a paratope mimic of the monoclonal antibody Infliximab (Remicade®) and 
provides access to a range of highly pre-organised molecular constructs bearing three different 
peptide segments. This approach may find wide applications for development of protein-protein 
interaction disruptors as well as synthetic vaccines. 
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 In the past we have used the highly pre-organized 
CycloTriVeratrylene (CTV) scaffold successfully for 
development of effective collagen mimics.2 More recently, 
preparation of collections of gp120 protein mimics, using these 
different scaffolds, showed that CTV-scaffolded gp120 epitope 
mimics were the most powerful protein mimics (IC50-values of 
the gp120-CD4 interaction in ELISA of 1.7 and 2.2 μM).12 
Therefore, we felt it was necessary to develop an orthogonally 
protected CTV derivative, so that the selected protein mimics can 
be re-synthesized. In this research we describe the synthesis of 
the highly pre-organized semi-orthogonally protected CTV 
scaffold as well as an example of sequential introduction of three 
different cyclic peptides towards individual protein mimics. 
 
2. Results and discussion 
Similar to the recently described semi-orthogonal alkyne 
functionalized TAC-scaffold 1 (Figure 2), we wished to develop 
a semi-orthogonally alkyne functionalized CTV scaffold 2. 
Figure 2. Recently developed orthogonally protected TAC-scaffold13 1 and 
the orthogonally protected (+)-CTV scaffold 2.  
 However, in contrast to the TAC-scaffold,1,3 1 orthogonality 
of protection cannot be achieved during synthesis of the CTV  
scaffold21 6 (Scheme 1) itself, but has to be introduced post-
synthesis, thus, after completion of its synthesis. First, it was 
attempted to mono-functionalize the CTV scaffold 6 with 
propargyl bromide (14). This gave only low yields of CTV 
propargyl ether 7, together with di-alkylated derivative 8 and 
starting material, which were hardly separable. 
 Scheme 1. Synthesis of CTV scaffold 6 and mono-alkylation attempt. 
Therefore, it was attempted to temporarily protect two 
phenolic hydroxy functionalities and subsequently alkylate the 
remaining free hydroxy group. Attempts to protect two hydroxy 
functionalities as bis-esters or bis-silylethers were unsuccessful. 
Nevertheless, the desired temporary protection was achieved 
using THP protecting group, which afforded the desired di-THP 
derivative 9 from CTV 6 under mild conditions in a decent 30% 
yield (Scheme 2). Moreover, the di-THP derivative 9 was easily 
separable from mono and tri-THP-ethers 10, which could then be 
converted back to CTV 6 in a moderate yield. Subsequently, di-
THP ether 9 was alkylated to give 11 followed by removal of the 
THP-protecting group leading to mono-propargyl ether 7 in a 
good (70% over 2 steps) yield.  
Scheme 2. Synthesis of mono-propargyl CTV 7 via di-THP-CTV ether 9 
 
Next, silyl protected alkynes were introduced onto the mono 
alkylated scaffold 7 (Scheme 3). Since the TIPS-group is more 
stable, alkyne bromide 21 was introduced first onto the propargyl 
CTV derivative 7.  Along with the desired mono-TIPS 
derivative 12 the di-TIPS side product 13 was formed. Because 
of the formation side product 13 and only 1.05 eq. of 21 used in 
the reaction, some starting material 7 remained unreacted and 
was recovered (25%). Finally, the mono-TIPS derivative 12 was 
alkylated with TES-protected alkyne bromide 15 to give the 
desired semi-orthogonally protected CTV scaffold derivative 2 in 
a good yield (72%) (Scheme 3). 
 
Scheme 3. Completion of the synthesis of the semi-orthogonally protected 
CTV scaffold 2. 
The preparation of the required silyl protected alkyne 
bromides 15 and 21 is shown in Scheme 4. First, a direct 
silylation of propargyl bromide 14 with TES-Cl was attempted 
(Scheme 4). 
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 Scheme 4. Synthesis of silyl protected alkyne bromides 15 and 21. 
However, the target TES-protected alkyne bromide 15 was 
obtained in a low yield partly due to formation of the substitution 
by-product 16. Here too, the THP group offered a remedy. 
Hence, the desired silyl protected alkyne bromides 15 and 21 
were prepared starting from propargyl alcohol 17 which was 
protected as a THP ether 18. Following the protection, the free 
alkyne of the THP ether 18 was silylated with either TES-Cl or 
TIPS-Cl to give corresponding TES and TIPS protected 
analogues 19 and 20 respectively. Lastly, bromination and 
concomitant removal of the THP ethers of the silyl protected 
alkynes 19 and 20 led to the formation of the desired silyl 
protected alkyne bromides 15 and 21.  
To illustrate the potential of the semi-orthogonally protected 
CTV scaffold 2 for the construction of protein mimics, three 
cyclized peptides obtained by using our recently described polar 
hinge10, were sequentially introduced in a convenient "click and 
cleavage" approach. The peptide segments represent CDR-loops 
of the monoclonal antibody Infliximab (Remicade®), which is a 
powerful tumor necrosis factor α (TNF α) inhibitor. The amino 
acid sequences of these peptides were derived from the X-ray 
structure of an Infliximab-TNFα-trimer complex22 After their 
solid phase syntheses, the N,C-terminal dicysteine containing 
peptides were cleaved and deprotected, followed by 
chemoselective cyclization using polar hinge 22 leading to cyclic 
peptides 26-28 (Scheme 5). The azide functionality in the hinge 
22 allowed ligation of the resulting cyclic peptides by Cu(I)-
catalyzed azide alkyne cycloaddition (CuAAC) onto the CTV 
scaffold derivative 2 in a similar manner as was described 
previously for semi-orthogonally protected TAC scaffold 1.13,14 
However, no microwave irradiation was necessary and the 
solvent mixture was changed to i-PrOH/DMF/H2O 4/3/1, v/v/v 
for complete dissolution of the CTV scaffold derivative 2. Thus, 
first cyclic peptide 26 was ligated to 2 via CuAAC to give the 
CTV scaffold containing one peptide loop (29), in a  
 
Scheme 5. Sequential ligation of cyclic peptides 26, 27, 28 onto the 
semi-orthogonally protected CTV scaffold 2. 
 good yield (70%) (Scheme 5). Next, the TES protecting 
group was mildly removed using AgNO3 leading to deprotected 
scaffold derivative 30 (68%) and cyclic peptide 27 was ligated 
via CuAAC to afford the CTV scaffold containing two peptide 
loops i.e. 31 (40%). The last peptide loop 28 was introduced by 
CuAAC after removal of the TIPS protecting group (TBAF·3H2O 
in DMF, 42%) to complete the molecular construction of the 
three peptide loops containing protein mimic 33 of Infliximab in 
40% yield.  
3. Conclusion 
We have described the construction of an orthogonally 
protected molecular scaffold, which is probably the most pre-
organized scaffold presently available for the construction of 
protein mimics. Moreover, owing to the protection group strategy 
desired different peptide segments can be introduced 
corresponding to different epitopes, paratopes, protein hot-spots 
etc., which offers a great potential for applications of this CTV 
scaffold including antibody mimics and synthetic vaccines.  
In this research we have described a versatile construction of a 
mimic (33) of the anti-TNFα monoclonal antibody Infliximab 
(Remicade®) containing three different cyclic peptides 
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corresponding to three CDR-loops of this antibody. These cyclic 
peptides were introduced in "click and cleavage" approach, in 
which sequentially a peptide loop was ligated, followed by 
cleavage of the protecting group and repeating this procedure. In 
establishing this procedure the mono and dipeptide loop 
constructs were purified and characterized, but we think that this 
procedure has possibilities for a fast and easy preparation of 
protein mimics in a "kit-like" manner with only purification after 
the last stage. 
Under present investigation is the biological evaluation of the 
obtained bio-molecular construct. Although a strong biological 
activity is of course hoped for, realistically, probably libraries of 
this antibody mimic have to be prepared first, before finding hits 
with decent biological activities. However, this will be possible 
using our earlier described combinatorial approach for obtaining 
collections of discontinuous epitopes11, now to be applied to the 
paratope of Infliximab. Promising hits can then be re-synthesized 
for validation and on a larger scale using the orthogonally 
protected CTV scaffold described here. 
Finally, it is important to realize that also other (bio) 
molecular constructs e.g. different carbohydrate constructs, 
nucleic acid can be selectivity ligated to this semi-orthogonally 
protected CTV scaffold, which may open up a plethora of 
applications. 
4. Experimental part  
4.1. General information 
All reagents and solvents were used as received. 1H NMR and 
the 13C NMR spectra were recorded on Bruker 400 MHz 
Spectrospin spectrometer (400 MHz, 100 MHz) in CDCl3. 
Chemical shifts (δ) are reported in parts per million (ppm) 
relative to trimethylsilane (TMS, 0.00 ppm) or CDCl3 
(7.26 ppm). Splitting patterns are designated as singlet (s), 
doublet (d), triplet (t), quartet (q), multiplet (m). TLC was carried 
out on silica gel plates (Merck 60F254) and the visualization was 
performed by both, the UV detection (254 nm) and staining 
solutions (cerium molybdenate, potassium permanganate) 
followed by heating. For column chromatography, silica gel 
Geduran® Si 60 (40 - 63 μm) was used. All chemicals and 
solvents were purchased from regular commercial sources in 
analytical or HPLC grade and were not further purified. Dry 
solvents (THF, DCM) were dispensed from Pure Solv™ 500 
Solvent Purification System and other dry solvents (acetonitrile) 
were prepared from commercially available HPLC grade solvents 
by removal of residual water with 4Å molecular sieves overnight. 
HRMS-ESI was recorded on Bruker microTOFq High Resolution 
Mass Spectrometer in a positive mode. EI-MS was recorded on 
Jeol MSTATION JMS-700 in a positive mode.  
Fmoc-amino acids were obtained from Activotec (Cambridge, 
United Kingdom) and N,N,N′,N′-Tetramethyl-O-(6-chloro-1H-
benzotriazol-1-yl)uranium hexafluorophosphate (HCTU) was 
obtained from Matrix Innovation (Quebec, Canada). Tentagel 
S RAM resin (particle size 90μm, capacity 0.25 mmol.g-1) was 
obtained from IRIS Biotech (Marktredwitz, Germany). Methyl 
tert-butyl ether (MTBE), n-hexane (HPLC grade) and TFA were 
obtained from Aldrich (Milwaukee, USA). DMF (Peptide grade) 
was obtained from VWR (Lutterworth, United Kingdom). 
Piperidine and DiPEA were obtained from AGTC Bioproducts 
(Hessle, United Kingdom), and 1,2-ethanedithiol (EDT) was 
obtained from Merck (Darmstadt, Germany). HPLC grade 
CH2Cl2 and acetonitrile were obtained from Fischer Scientific 
(Loughborough, United Kingdom). Solid phase peptide synthesis 
was performed on a PTI Tribute-UV peptide synthesizer. 
Lyophilizations were performed on a Christ Alpha 2-4 LDplus 
apparatus. Analytical high pressure liquid chromatography 
(HPLC) was carried out on a Shimadzu instrument comprising a 
communication module (CBM-20A), autosampler (SIL-20HT), 
pump modules (LC-20AT), UV/Vis detector (SPD-20A) and 
system controller (Labsolutions V5.54 SP), with a Phenomenex 
Gemini C18 column (110 Å, 5 μm, 250 × 4.60 mm). UV 
measurements were recorded at 214 and 254 nm, using a standard 
protocol: 100% buffer A (acetonitrile/H2O 5:95 with 0.1% TFA) 
for 2 min followed by a linear gradient of buffer B 
(acetonitrile/H2O 95:5 with 0.1% TFA) into buffer A (0-100%) 
over 30 min at a flow rate of 1.0 mL·min-1. Purification of 
peptidic compounds was performed on an Agilent Technologies 
1260 infinity preparative system using UV detector with a 
Phenomenex Gemini C18 column (110 Å, 10 μm, 250 × 20 mm). 
Auto-collection of fractions was based on the UV measurements 
at 214 nm, using either 100% buffer A or 95% buffer A with 5% 
buffer B for 5 min followed by and linear gradient of buffer B 
into buffer A (specified for each compound) over 65 min at a 
flow rate of 12.5 mL·min-1 using the same buffers as described 
for analytical HPLC. Liquid chromatography mass spectrometry 
(LCMS) was carried out on a Thermo Scientific LCQ Fleet 
quadrupole mass spectrometer with a Dionex Ultimate 3000 LC 
using a Dr. Maisch Reprosil Gold 120 C18 column (110 Å, 3 μm, 
150 × 4.0 mm), using a 0-100% linear gradient of buffer B into 
buffer A and the same flow rate and buffers as described for 
analytical HPLC.  
 
4.2. Scaffold synthesis and derivatization 
1-O-allyl-vanillyl alcohol (4) Compound 4 was prepared 
according to a modified literature procedure.21 To the solution of 
vanillyl alcohol 3 (55.0 g, 356.8 mmol) in acetone (82 mL), 
K2CO3 (49.8 g, 360.3 mmol) and allyl bromide (34.0 mL, 
392.5 mmol) were added. The resulting mixture was stirred under 
reflux for 4.5 h. Afterwards, acetone was removed under reduced 
pressure and the residue was partioned between CH2Cl2 (500 mL) 
and water (400 mL). The organic phase was then dried over 
MgSO4, and filtered. Crude 4 (65.1 g, 94.0%) was obtained upon 
removal of CH2Cl2 under reduced pressure. The crude product 
was crystallized from MTBE/n-hexane affording 4 (60.3 g, 
87.0%) as white crystals. Rf = 0.32 (n-hexane/EtOAc 6/4). 
1H 
NMR (400 MHz, CDCl3): δ = 1.94 (s, 1H), 3.89 (s, 3H), 4.61 - 
4.63 (m, 4H), 5.29 (dd, J = 1.4 Hz, 10.5 Hz, 1H), 5.41 (dd, J = 
1.5 Hz, 17.3 Hz, 1H), 6.04 - 6.14 (m, 1H), 6.86 (s, 2H), 6.94 (s, 
1H). 13C NMR (100 MHz, CDCl3): δ = 55.9, 65.2, 70.0, 110.9, 
113.5, 117.9, 119.3, 133.3, 134.1, 147.5, 149.6. HRMS-ESI: m/z 
calcd for C11H14NaO3 [M+Na]
+, 217.0835; found, 217.0834.This 
compound has been also previously reported.21  
Tris(O-allyl) CTV (5) Compound 5 was prepared according to 
a literature procedure21 in the following manner. Compound 4 
(57.4 g, 295.5 mmol) was dissolved in MeOH (340 mL) and the 
solution was cooled to 0°C resulting in the formation of a 
precipitate. Next, upon the dropwise addition of 60% (aq) HClO4 
(171 mL) the precipitate dissolved and the solution became pink. 
Once HClO4 was added, the reaction mixture was allowed to 
warm up to RT and stirred for 16.5 h during which white 
precipitate gradually formed. Afterwards, the reaction mixture 
was diluted with CH2Cl2 (570 mL) and washed with water 
(7 × 570 mL) till the neutral pH was reached, which can be also 
recognized by the change of the color of the organic layer from 
pink to yellow. The organic phase was then dried over MgSO4, 
filtered, concentrated under reduced pressure to give pale yellow 
solid which was suspended in Et2O (100 mL) and stirred for 2 h 
before being filtered off. The filtrate was washed with Et2O 
(3 × 30 mL) and dried on high vacuum. Compound 5 (27.1 g, 
52.0%) was obtained as a white solid. Rf = 0.47 (n-hexane/EtOAc 
6/4). 1H NMR (400 MHz, CDCl3): δ = 3.54 (d, J = 13.9 Hz), 3.86 
(s, 9H), 4.56 - 4.66 (m, 6H), 4.77 (d, J = 13.7 Hz, 3H), 5.28 (dd, 
J = 1.4 Hz, 10.5 Hz, 3H), 5.39 (dd, J = 1.6 Hz, 17.3 Hz, 3H), 
6.04 - 6.13 (m, 3H), 6.82 (s, 3H), 6.88 (s, 3H). 13C NMR 
(100 MHz, CDCl3): δ = 36.3, 55.9, 70.0, 113.5, 115.5, 117.3, 
131.6, 132.2, 133.6, 146.6, 148.0. HRMS-ESI: m/z calcd for 
C33H36NaO6 [M+Na]
+, 551.2404; found, 551.2391.This 
compound has been also previously reported.21  
CTV-triOH (6) Compound 6 was prepared according to a 
modified literature procedure.21 To the solution of 5 (26.0 g, 
49.2 mmol) in dioxane/EtOH (130 mL/230 mL), 10% Pd/C 
(5.4 g), 65% (aq) HClO4 (5.4 mL) were added and the resulting 
reaction mixture was stirred under nitrogen atmosphere at 65°C 
for 24 h and then for 48 h at RT. Next, catalyst was filtered off 
and washed with dioxane (50 mL) and CH2Cl2 (200 mL). The 
filtrate was then washed with water (2 × 700 mL, 2 × 500 mL), 
aqueous layer was extracted with CH2Cl2 (100 mL) and the 
combined organic layer was dried over MgSO4, filtered, 
concentrated under reduced pressure to ca 100 mL, and allowed 
to crystallize. The crystals were filtered off, washed with cold 
CH2Cl2 (3 × 30 mL) and dried on a high vacuum to afford 6 
(10.5 g, 52.1%) as white crystals. Rf = 0.18 (n-hexane/EtOAc 
1/1). 1H NMR (400 MHz, CDCl3): δ = 3.50 (d, J = 13.9 Hz), 3.85 
(s, 9H), 4.72 (d, J = 13.7 Hz, 3H), 5.41 (s, 3H), 6.79 (s, 3H), 6.88 
(s, 3H). 13C NMR (100 MHz, CDCl3): δ = 36.3, 56.1, 112.3, 
115.5, 131.2, 132.5, 144.2, 145.3. HRMS-ESI: m/z calcd for 
C24H24NaO6 [M+Na]
+, 431.1465; found, 431.1464.This 
compound has been also previously reported.23  
Di(O-THP) CTV-OH (9), Mono(O-THP) CTV-diOH and 
Tri(O-THP) CTV (10)  
To a suspension of CTV 6 (5.0 g, 12.4 mmol) in CHCl3 
(124 mL), DHP (2.3 mL, 25.4 mmol) and p-TsOH monohydrate 
(0.02 g, 0.1 mmol) were added. After 2 h of stirring, during 
which the reaction mixture became pink, additional DHP 
(1.2 mL, 12.3 mmol) was added, which resulted in the formation 
of a solution which was stirred for an additional 1 h. Afterwards, 
the reaction mixture was diluted with Et2O (125 mL) followed by 
immediate addition of saturated NaHCO3 (50 mL). Direct 
addition of CHCl3 or saturated NaHCO3 to reaction mixture was 
attempted too but lead to partial decomposition in certain cases. 
Next, the aqueous layer was extracted with Et2O (100 mL) and 
the combined organic layer was dried over MgSO4, filtered, and 
solvents were removed under reduced pressure. The crude 
product was purified by a column chromatography 
(n-hexane/EtOAc 2.5/1 to n-hexane/EtOAc 1/1). Compound 6 
(2.1 g, 29.9%) was obtained as a yellow foam. Rf = 0.33 
(n-hexane/EtOAc 1/1). 1H NMR (400 MHz, CDCl3): δ = 1.52 -
1.74 (m, 6H), 1.79 - 1.95 (m, 4H), 1.99 - 2.08 (m, 2H), 3.47 - 
3.59 (m, 5H), 3.81 - 3.91 (m, 10H), 3.99- 4.06 (m, 1H), 4.69 - 
4.75 (m, 3H), 5.17 - 5.19 (m, 1H), 5.40 - 5.45 (m, 1H), 5.47 (s, 
1H), 6.81 (d, J = 3.1 Hz, 1H), 6.84 (d, J = 1.9 Hz, 1H), 6.85 (s, 
1H), 6.90 (dd, J = 1.8 Hz, 5.7 Hz, 1H), 7.11- 7.15 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 18.8, 19.0, 19.1, 25.4, 30.4, 
30.6, 36.4, 36.5, 55.9, 56.0, 56.3, 56.4, 56.5, 56.6, 62.0, 62.3, 
97.2, 97.3, 98.2, 98.3, 112.3, 113.9, 114.1, 114.3, 114.4, 115.5, 
115.6, 115.7, 115.8, 118.7, 119.0, 119.5, 120.0, 120.1, 131.5, 
131.6, 131.7, 131.9, 132.0, 132.1, 132.3, 132.4, 133.1, 133.3, 
133.9, 134.0, 144.1, 144.2, 144.9, 145.0, 145.1, 145.3, 145.4, 
148.6, 148.7, 149.1. HRMS-ESI: m/z calcd for C34H40NaO8 
[M+Na]+, 599.2615; found, 599.2592. Along with the product 9, 
a mixture of 10 was obtained as a yellow foam. For analytical 
purposes 1H NMR spectra of pure Mono(O-THP) CTV-diOH and 
Tri(O-THP) CTV were measured before the compounds were 
mixed for recovery of compound 6. Mono(O-THP) CTV-diOH: 
1H NMR (400 MHz, CDCl3): δ = 1.56 - 1.71 (m, 3H), 1.81 - 2.06 
(m, 3H), 3.47 - 3.59 (m, 4H), 3.82 - 3.89 (m, 9.5H), 4.00 - 4.05 
(m, 0.5H), 4.65 - 4.71 (m, 3H), 5.17 (s, 0.5H), 5.42 (s, 0.5H), 
5.56 (s, 2H), 6.78 - 6.91 (m, 5H), 7.12 (s, 1H). Rf = 0.20 
(n-hexane/EtOAc 1/1). Tri(O-THP) CTV: 1H NMR (400 MHz, 
CDCl3): δ = 1.52 - 1.69 (m, 9H), 1.79 - 2.03 (m, 9H), 3.47 - 3.58 
(m, 6H), 3.80 - 3.90 (m, 10.5H), 3.98 - 4.04 (m, 1.5H), 4.68 - 
4.72 (m, 3H), 5.18 (m, 1.5H), 5.39 (m, 1.5H), 6.84 (s, 3H), 7.11 - 
7.13 (m, 3H). Rf = 0.52 (n-hexane/EtOAc 1/1). 
Recovery of CTV-triOH (6) To the suspension of side products 
10 in MeOH (13 mL per 1 g of mixture), 1M HCl (2.6 mL per 
1 g of mixture) was added and the reaction mixture was stirred 
for 2 h during which a white precipitate was formed. Afterwards, 
MeOH was removed under reduced pressure and the creamy 
residue was dissolved in EtOAc/MeOH (40/1, v/v, 130 mL per 
1 g of mixture) and washed with water/brine (1/1, v/v, 40 mL per 
1 g of mixture). The aqueous layer was extracted with EtOAc 
(25 mL per 1 g of mixture) and the combined organic layer was 
washed with brine (25 mL per 1 g of mixture), dried over 
MgSO4, filtered, and concentrated under reduced pressure to a 
low volume. White precipitate was formed during removal of 
solvents. The suspension was kept at +4°C  overnight before the 
white precipitate was filtered off and washed with EtOAc to give 
compound 6 ( typically between 58% - 74%).  
Di(O-THP)-O-propargyl CTV (11) To the solution of 
compound 9 (1.0 g, 1.7 mmol) in acetonitrile (17 mL) Cs2CO3 
(0.6 g, 1.9 mmol) was added, followed by the addition of 
propargyl bromide (80% in toluene) (0.23 mL, 2.1 mmol) and the 
resulting reaction mixture was stirred for 2.5 h. Afterwards, 
acetonitrile was removed under reduced pressure and the viscous 
residue was diluted with EtOAc (100 mL) and washed with water 
(100 mL). Aqueous layer was extracted with EtOAc (50 mL) and 
combined organic layer was washed with brine (50 mL), dried 
over MgSO4, filtered, and EtOAc was removed under reduced 
pressure. The crude product was purified by a column 
chromatography (n-hexane/EtOAc 9/1 to n-hexane/EtOAc 7/3). 
Compound 11 (0.8 g, 76.8%) was obtained as a white foam. 
Rf = 0.51 (n-hexane/EtOAc 1/1). 
1H NMR (400 MHz, CDCl3): 
δ = 1.53 - 1.69 (m, 6H), 1.80 - 2.05 (m, 6H), 2.39 (s, 1H), 
3.47 - 3.57 (m, 5H), 3.80 - 3.83 (m, 10H), 3.98 - 4.03 (m, 1H), 
4.67 - 4.73 (m, 5H), 5.17 - 5.20 (m, 1H), 5.40 (s, 1H), 6.83 - 6.84 
(m, 2H), 6.87 (s, 1H), 7.01 (d, J = 5.8 Hz, 1H), 7.12 - 7.15 (m, 
2H). 13C NMR (100 MHz, CDCl3): δ = 18.7, 19.0, 25.3, 30.4, 
30.5, 36.4, 36.5, 55.8, 56.0, 56.2, 56.3, 56.4, 56.6, 56.7, 57.0, 
61.9, 62.2, 75.8, 79.1, 97.1, 97.2, 98.1, 98.2, 98.3, 113.4, 113.5, 
113.8, 114.1, 114.6, 114.7, 114.8, 116.4, 116.5, 116.6, 118.6, 
118.9, 119.0, 119.6, 119.7, 119.8, 131.3, 131.4, 131.5, 131.6, 
131.7, 131.9, 132.0, 132.1, 132.2, 132.3, 133.1, 133.2, 133.8, 
133.9, 134.0, 145.0, 145.1, 145.2, 145.3, 148.4, 148.5, 148.6, 
148.9, 149.1. HRMS-ESI: m/z calcd for C37H42NaO8 [M+Na]
+, 
637.2772; found, 637.2755. 
O-Propargyl CTV-diOH (7) Compound 11 (790 mg, 
1.29 mmol) was suspended in MeOH (20 mL) and then 1M HCl 
(1 mL) was added. The reaction mixture was stirred for 1 h 
during which the suspension turned into a yellow solution. 
Afterwards, MeOH was removed under reduced pressure and the 
viscous residue was diluted with EtOAc (40 mL) and washed 
with water (30 mL). Next, the aqueous phase was extracted with 
EtOAc (20 mL) and the combined organic layer was washed with 
brine (30 mL), dried over MgSO4, filtered, and EtOAc was 
removed under reduced pressure. The crude product was purified 
by a column chromatography (CHCl3 to CHCl3/MeOH 50/1). 
Compound 7 (524 mg, 91.4%) was obtained as a white foam.  
Rf = 0.25 (n-hexane/EtOAc 1/1). 
1H NMR (400 MHz, CDCl3): 
δ = 2.44 (t, J = 2.4 Hz, 1H), 3.49 - 3.56 (m, 3H), 3.84 (s, 3H), 
3.86 (s, 6H), 4.70 - 4.77 (m, 5H), 5.39 (s, 1H), 5.41 (s, 1H), 6.79 
(s, 1H), 6.84 (s, 1H), 6.85 (s, 1H), 6.89 (s, 1H), 6.90 (s, 1H), 7.01 
(s, 1H). 13C NMR (100 MHz, CDCl3): δ = 56.8, 57.9, 76.4, 78.0, 
79.9, 113.0, 113.1, 114.4, 116.3, 117.4, 131.9, 132.5, 132.9, 
133.3, 134.3, 144.9, 145.9, 146.0, 149.2. HRMS-ESI: m/z calcd 
for C27H26NaO6 [M+Na]
+, 469.1622; found, 469.1603. 
O-Propargyl-O-(TIPS)propargyl CTV-OH (12), 
O-Propargyl bis[O-(TIPS)propargyl] CTV (13) Cs2CO3 (181 mg, 
0.56 mmol) was added to the solution of compound 7 (226 mg, 
0.51 mmol) in dry acetonitrile (20 mL). Next, a solution of 
compound 21 (146 mg, 0.53 mmol) in dry acetonitrile (3 mL) 
was added dropwise. The reaction mixture was stirred under 
nitrogen atmosphere for 20 h. Afterwards, acetonitrile was 
removed under reduced pressure and the residue was suspended 
in Et2O (40 mL) and washed with 1M KHSO4 (40 mL). The 
aqueous layer was extracted with Et2O (20 mL) and the 
combined organic layer washed with brine (40 mL), dried over 
MgSO4, filtered, and Et2O was removed under reduced pressure. 
The crude product was purified by a column chromatography 
(CH2Cl2 to CH2Cl2/MeOH 100/1) to afford compound 13 (93 mg, 
23.2%) as a pale yellow solid. Rf = 0.87 (n-hexane/EtOAc 1/1). 
1H NMR (400 MHz, CDCl3): δ = 1.02 (m, 42H), 2.45 (t, 
J = 2.4 Hz, 1H), 3.50 - 3.57 (m, 3H), 3.83 - 3.84 (m, 9H), 
4.57 - 4.86 (m, 9H), 6.83 (s, 2H), 6.85 (s, 1H), 7.00 (s, 1H), 7.14 
(s, 1H), 7.16 (s, 1H). 13C NMR (100 MHz, CDCl3): δ = 11.1, 
18.6, 36.5, 56.0, 56.2, 57.0, 58.6, 75.7, 79.1, 89.2, 102.5, 113.5, 
113.9, 116.6, 117.6, 117.9, 131.5, 131.7, 133.3, 133.6, 145.3, 
145.9, 146.0, 148.5, 148.8. HRMS-ESI: m/z calcd for 
C51H70NaO6Si2 [M+Na]
+, 857.4603; found, 857.4569. Compound 
12 (139 mg, 42.9%) was obtained as a yellow amorphous solid. 
Rf = 0.62 (n-hexane/EtOAc 1/1). 
1H NMR (400 MHz, CDCl3): 
δ = 1.01 (m, 21H), 2.44 (m, 1H), 3.47 - 3.54 (m, 3H), 3.83 (s, 
9H), 4.58 - 4.84 (m, 7H), 5.44 (d, J = 9.4 Hz, 1H), 6.79 - 6.85 (m, 
3H), 6.89 (d, J = 6.8 Hz, 1H), 6.99 (d, J = 6.3 Hz, 1H), 7.13 (d, 
J = 3.3 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 11.1, 18.6, 
36.4, 56.0, 56.1, 56.2, 57.0, 57.1, 58.6, 75.6, 75.7, 79.1, 79.2, 
89.2, 102.6, 112.1, 112.4, 113.5, 113.7, 113.9, 115.7, 116.6, 
116.8, 117.9, 131.1, 131.3, 131.4, 131.6, 131.7, 131.9, 132.4, 
133.6, 133.7, 144.2, 145.3, 145.4, 145.9, 148.5, 145.7, 145.8. 
HRMS-ESI: m/z calcd for C39H48NaO6Si [M+Na]
+, 663.3112; 
found, 663.3092. Starting material, compound 7, (57 mg, 25.2%) 
was recovered.  
O-Propargyl-O-(TIPS)propargyl-O-(TES)propargyl CTV (2) 
To the suspension of compound 12 (303 mg, 0.47 mmol) in dry 
acetonitrile (5 mL) Cs2CO3 (162 mg, 0.50 mmol) was added 
followed by the addition of the solution of compound 15 
(121 mg, 0.52 mmol) in dry acetonitrile (0.5 mL). The resulting 
mixture was stirred for 5.5 h and then acetonitrile was removed 
under reduced pressure. The viscous residue was suspended in 
Et2O (40 mL) and washed with water (30 mL). The aqueous layer 
was extracted with Et2O (30 mL) and the combined organic layer 
washed with brine (20 mL), dried over MgSO4, filtered, and Et2O 
was removed under reduced pressure. The crude product was 
purified by a column chromatography (n-hexane/Et2O 3/1 to n-
hexane/Et2O 2/1). Compound 2 (269 mg, 71.7%) was obtained as 
a white foam. Rf = 0.60 (n-hexane/EtOAc 3/1). 
1H NMR 
(400 MHz, CDCl3): δ = 0.58 (m, 6H), 0.94 (m, 9H), 1.02 (m, 
21H), 2.45 (m, 1H), 3.50 - 3.57 (m, 3H), 3.84 (m, 9H), 4.56 --
4.85 (m, 9H), 6.83 - 6.85 (m, 3H), 7.00 (s, 1H), 7.09 - 7.15 (m, 
2H). 13C NMR (100 MHz, CDCl3): δ =  4.2, 7.4, 11.1, 18.6, 36.5, 
56.0, 56.1, 57.0, 58.5, 58.6, 58.7, 75.7, 79.1, 89.2, 90.3, 101.8, 
102.5, 113.5, 113.6, 114.0, 116.7, 117.9, 131.5, 131.6, 133.4, 
133.5, 133.7, 145.4, 145.9, 146.0, 148.5, 148.6, 148.8. 
HRMS-ESI: m/z calcd for C48H64NaO6Si2 [M+Na]
+, 815.4134; 
found, 815.4102. 
4.3. Preparation of silyl alkyne bromides 
O-THP Propargyl alcohol (18) Compound 18 was prepared 
according to a literature procedure.24 To the solution of propargyl 
alcohol 17 (2.6 mL, 44.6 mmol) and p-TsOH monohydrate 
(0.09 g, 0.5 mmol) in CH2Cl2 (45 mL) DHP (4.3 mL, 46.8 mmol) 
was added dropwise at 0°C. After stirring for 5 min at 0°C, the 
reaction mixture was allowed to warm up to RT and was stirred 
for 1 h. Next, the reaction mixture was washed with saturated 
NaHCO3 (30 mL) and the aqueous layer was extracted with 
CH2Cl2 (45 mL). The combined organic layer dried over MgSO4, 
filtered, and concentrated under reduced pressure to give 
compound 18 (6.1 g, 97.2%) as a yellow oil. Rf = 0.30 
(n-hexane/Et2O 95/5). 
1H NMR (400 MHz, CDCl3): 
δ = 1.50 - 1.67 (m, 4H), 1.70 - 1.89 (m, 2H), 2.41 (t, J = 2.4 Hz, 
1H), 3.52 - 3.57 (m, 1H), 3.82 - 3.87 (m, 1H), 4.27 (ddd, 
J = 2.4 Hz, 11.3 Hz, 15.8 Hz, 2H), 4.83 (t, J = 3.4 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ = 19.0, 25.3, 30.2, 53.9, 61.9, 
74.0, 79.7, 96.8. MS-CI: m/z calcd for C8H12O2 [M+H]
+, 141; 
found, 141. This compound has been also previously reported.25 
O-THP (TIPS)Propargyl alcohol(20)Compound 20 was 
prepared according to a modified literature procedure.26 A 
solution of compound 18 (1.0 g, 7.1 mmol) in dry THF (20 mL) 
was cooled to -78°C. Next, n-BuLi (3.0 mL, 7.5 mmol, 2.5M in 
hexane) was added dropwise and the reaction mixture was stirred 
under nitrogen atmosphere at -78°C for 1 h before TIPS-Cl 
(1.7 mL, 7.9 mmol) was added. The reaction mixture was then 
allowed to warm up to RT and stirred under nitrogen atmosphere 
for additional 4 h before it was quenched by addition of saturated 
NH4Cl (15 mL). The reaction mixture was extracted with Et2O 
(2 × 25 mL), dried over MgSO4, filtered, and Et2O was carefully 
removed under reduced pressure with water bath kept at RT. The 
crude product was purified by a column chromatography 
(n-hexane to n-hexane/Et2O 99/1) to afford 20 (1.8 g, 85.9%) as a 
clear oil. Rf = 0.44 (n-hexane/Et2O 95/5). 
1H NMR (400 MHz, 
CDCl3): δ = 1.07 (m, 21H), 1.51 - 1.65 (m, 4H), 1.71 - 1.87 (m, 
2H), 3.50 - 3.55 (m, 1H), 3.83 - 3.89 (m, 1H), 4.31 (ddd, 
J = 2.4 Hz, 6.3 Hz, 16.1 Hz, 2H), 4.91 (t, J = 3.4 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ = 11.2, 18.6, 19.2, 25.4, 30.4, 
54.7, 62.2, 87.0, 96.3, 103.4. HRMS-ESI: m/z calcd for 
C17H32NaO2Si [M+Na]
+, 319.2064; found, 319.2049. This 
compound has been also previously reported.27 
 (TIPS)Propargyl bromide (21) Compound 21 was prepared 
according to a modified literature procedure.26 Br2 (130 μL, 
2.53 mmol) was added dropwise at 0°C to a solution of Ph3P 
(697 mg, 2.66 mmol) in dry CH2Cl2 (10 mL) and the solution was 
stirred under nitrogen atmosphere for 30 min during which a 
white precipitate was formed. Next, compound 20 (750 mg, 
2.53 mmol) was added dropwise and the reaction mixture was 
stirred under nitrogen atmosphere at 0°C for additional 5 h during 
which the white precipitate dissolved. The reaction mixture was 
then diluted with water (15 mL) and extracted with n-hexane 
(2 × 20 mL). The combined organic layer was washed with 
saturated NaHCO3 (10 mL), dried over MgSO4, filtered, and 
n-hexane was carefully removed under reduced pressure with 
water bath kept at RT. The crude product was purified by a 
column chromatography using (n-hexane) to afford 21 (682 mg, 
98.0%) as a clear oil. Rf = 0.69 (n-hexane). 
1H NMR (400 MHz, 
CDCl3): δ = 1.07 (m, 21H), 3.95 (s, 2H). 13C NMR (100 MHz, 
CDCl3): δ = 11.2, 15.0, 18.5, 89.2, 101.9. This compound has 
been also previously reported.27 
O-THP (TES)Propargyl alcohol (19) Compound 19 was 
prepared according to a modified literature procedure.27 A 
solution of compound 18 (1.0 g, 7.1 mmol) in dry THF (20 mL) 
was cooled to -78°C. Next, n-BuLi (3.0 mL, 7.5 mmol, 2.5M in 
hexane) was added dropwise and the reaction mixture was stirred 
under nitrogen atmosphere at -78°C for 1 h before TES-Cl 
(1.3 mL, 7.9 mmol) was added. The reaction mixture was then 
allowed to warm up to RT and stirred under nitrogen atmosphere 
for additional 4 h before it was quenched by addition of saturated 
NH4Cl (15 mL). The reaction mixture was extracted with Et2O 
(2 × 25 mL), dried over MgSO4, filtered, and Et2O was carefully 
removed under reduced pressure with water bath kept at RT. The 
crude product was purified by a column chromatography using 
(n-hexane to n-hexane/Et2O 99/1) to afford 19 (1.6 g, 87.9%) as a 
clear oil. Rf = 0.42 (n-hexane/Et2O 95/5). 
1H NMR (400 MHz, 
CDCl3): δ = 0.57 - 0.64 (m, 6H), 0.95 - 1.02 (m, 9H), 1.50 - 1.67 
(m, 4H), 1.70 - 1.87 (m, 2H), 3.50 - 3.55 (m, 1H), 3.82 - 3.88 (m, 
1H), 4.29 (s, 2H), 4.86 (t, J = 3.4 Hz, 1H). 13C NMR (100 MHz, 
CDCl3): δ = 4.3, 7.4, 19.1, 25.4, 30.3, 54.7, 62.0, 82.3, 96.5, 
102.7. HRMS-ESI: m/z calcd for C14H26NaO2Si [M+Na]
+, 
277.1594; found, 277.1584. Although compound 8 has been also 
previously reported,28 no spectroscopic data of compound 8 are 
available. 
 (TES)Propargyl bromide (15) Compound 15 was prepared 
according to a modified literature procedure.26 Br2 (0.3 mL, 
5.9 mmol) was added dropwise at 0°C to a solution of Ph3P 
(1.6 g, 6.2 mmol) in dry CH2Cl2 (23.6 mL) and the solution was 
stirred under nitrogen atmosphere for 30 min during which a 
white precipitate was formed. Next, compound 19 (1.5 g, 
5.9 mmol) was added dropwise and the reaction mixture was 
stirred under nitrogen atmosphere at 0°C for additional 5 h during 
which the white precipitate dissolved. The reaction mixture was 
then diluted with water (15 mL) and extracted with n-hexane 
(2 × 20 mL). The combined organic layer was washed with 
saturated NaHCO3 (10 mL), dried over MgSO4, filtered, and 
n-hexane was carefully removed under reduced pressure with 
water bath kept at RT. The crude product was purified by a 
column chromatography using (n-hexane) to afford 15 (1.1 g, 
82.3%) as a clear oil. Rf = 0.66 (n-hexane). 
1H NMR (400 MHz, 
CDCl3): δ = 0.61 (q, J = 7.9 Hz, 6H), 0.99 (t, J = 7.8 Hz, 9H), 
3.95 (s, 2H). 13C NMR (100 MHz, CDCl3): δ = 4.2, 7.3, 14.8, 
90.1, 101.2. This compound has been also previously reported.29  
4.4. Peptide synthesis and preparation of synthetic antibody 
4 .4 .1 .  Linear  pept ides   
General method for automated peptide synthesis: The peptides 
were synthesized on a PTI Tribute-UV peptide synthesizer. 
Tentagel S RAM resin (1.0 g, 0.25 mmol, 1.0 equiv or 400 mg, 
0.1 mmol, 1.0 equiv) was allowed to swell (3 x 10 min). 
Deprotection of the Fmoc group was achieved by treatment of the 
resin with 20% piperidine in DMF using the RV_top_UV_Xtend 
protocol from the Tribute-UV peptide synthesizer followed by a 
DMF washing step (5 x 30 sec). The Fmoc-protected amino acids 
(with the 0.1 mmol scale 5 equiv was used and with the 
0.25 mmol scale 4 equiv was used) were coupled using HCTU 
(with the 0.1 mmol scale 5 equiv was used and with the 
0.25 mmol scale 4 equiv was used) and DiPEA (with the 
0.1 mmol scale 10 equiv was used and with the 0.25 mmol scale 
8 equiv was used) in DMF, as a coupling system, with 2 min 
pre-activation. The coupling time was 10 min when the peptide 
was synthesized on a 0.1 mmol scale and 20 min when the 
0.25 mmol scale was conducted. After every coupling the resin 
was washed with DMF (6 x 30 sec). After the last amino acid 
coupling, the Fmoc group was cleaved using the normal 
deprotection conditions (described above) and the resulting free 
N-terminus was acetylated by treatment of the resin bound 
peptide with acetic anhydride (250 μL) and DiPEA (10 equiv for 
the 0.1 mmol scale and 8 equiv for the 0.25 mmol scale) in DMF 
using the standard coupling times (described above). After the 
last step the resin was washed with DMF (5 x 30 sec), DCM 
(5 x 30 sec), dried over a nitrogen flow for 10 min, followed by 
the cleavage of the resin-bounded peptide. Cleavage and global 
deprotection was achieved by treatment of the resin with 
TFA/H2O/TIS/EDT (10 mL for the 0.25 mmol scale and 5 mL 
for the 0.1 mmol scale, 90/5/2.5/2.5, v/v/v/v) for 3 hours. Next, 
the peptide was precipitated by dropwise addition of the TFA 
mixture to a cold (4 °C) solution of MTBE/n-hexane (1/1, 90 mL 
for the 0.25 mmol scale and 45 mL for the 0.1 mmol scale). After 
centrifugation (3500 rpm, 5 min) the supernatant was decanted 
and the pellet was re-suspended in MTBE/n-hexane (1/1, v/v) 
and centrifuged again. Finally, the pellet was washed twice with 
MTBE/n-hexane 50 mL (1/1, v/v), each time collected by 
centrifugation, dissolved in t-BuOH/H2O (1/1, v/v) and 
lyophilized to yield the crude linear peptide. Hence following 
peptides were obtained:  
Peptide 1·2TFA (23), Ac-CRSKSIYC-NH2, tR = 13.6 min. 
LCMS-ESI : average mass calcd [M]+: 1000.2; found: 1000.5.  
Peptide 2·TFA (24), Ac-CSNHWMNC-NH2, tR = 15.4 min. 
LCMS-ESI: average mass calcd [M]+: 1035.2; found: 1035.4.  
Peptide 2·2TFA (25), Ac-CSHSWRWC-NH2, tR = 15.7 min. 
LCMS-ESI: average mass calcd [M]+: 1105.3; found: 1105.5. 
4.4 .2 .  Cycl ic  pept ides  
All linear peptides were cyclized at the concentration of 1 mM 
in the following way. The crude linear peptide and the 
perhydro triazine hinge 22 were placed into a flask. Then, 
acetonitrile was added followed by the addition of aqueous 
solution of NH4HCO3 (20 mM, pH = 7.9) to form a 1/3 
(acetonitrile/NH4HCO3 v/v) mixture. The progress of the 
cyclization was checked by analytical HPLC after 30 min. In case 
of all the peptides, 30 min were sufficient for the complete 
cyclization. Next, acetonitrile was removed under reduced 
pressure and the remaining aqueous solution/suspension was 
lyophilized. The crude cyclic peptides were purified using 
preparative HPLC. The fractions containing product were 
combined and lyophilized yielding the desired cyclic peptides as 
a white fluffy solid.  
Cyclic peptide·2TFA (26), Purified 
using 5% to 30% of buffer B in buffer 
A. Average yield 22% (19 steps, 92% 
per step). tR = 14.1 min. LCMS-ESI: average mass calcd [M]
+: 
1250.4; found: 1250.5.  
Cyclic peptide 2·TFA (27), 
Purified using 5% to 30% of 
buffer B in buffer A. Average 
yield 20% (19 steps, 92% per step). tR = 15.3 min. LCMS-ESI: 
average mass calcd [M]+: 1285.4; found: 1285.5.  
Cyclic peptide 2·2TFA (28),. 
Purified using 5% to 40% of buffer 
B in buffer A. Average yield 11% 
(19 steps, 89% per step). tR = 16.0 min. LCMS-ESI: average 
mass calcd [M]+: 1355.5; found: 1355.5. 
4.4 .3 .  Prepara t ion  o f  a  synthet ic  ant ibody  mimic  
CTV Scaffold derivative (29) Semi-orthogonally protected 
CTV scaffold 2 (5.2 mg, 6.50 μmol), cyclic peptide 26 (10.6 mg, 
7.15 μmol), TBTA (1.0 mg, 1.95 μmol) were placed into a flask 
and degassed DMF (975 μL) was added and the mixture was 
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stirred under nitrogen atmosphere until clear solution was 
obtained. Next, degassed i-PrOH (1300 μL), deionized H2O 
(290 μL) were added followed by the addition of 0.2M aqueous 
sodium ascorbate (19.5 μL, 3.90 μmol) and 0.12M aqueous 
CuSO4 (16.3 μL, 1.95 μmol). The reaction mixture was stirred 
under nitrogen atmosphere and monitored by analytical HPLC 
which showed complete conversion after 1 h. Then, the solvents 
were removed with nitrogen stream giving red liquid residue 
(ca 50 μL) which was diluted with buffer B (150 μL) and buffer 
A (1200 μL). The resulting solution was centrifuged (4500 rpm, 
5 min) and purified using 5% to 100% of buffer B in buffer A. 
Scaffold derivative 29·2TFA (10.5 mg, 71.0%) was obtained as a 
white fluffy solid after lyophilization. tR = 29.1 min. LCMS-ESI: 
average mass calcd [M+2H]2+: 1022.8; found: 1022.5. 
CTV Scaffold derivative (30) To a solution of scaffold 
derivative 29·2TFA (10.3 mg, 4.53 μmol) in degassed DMF (680 
μL), degassed i-PrOH (910 μL), and deionized H2O (225 μL), 
AgNO3 (3.9 mg, 22.65 μmol) was added and the reaction mixture 
was stirred under nitrogen atmosphere and monitored by 
analytical HPLC which showed complete conversion after 1 h. 
Then, the solvents were removed with nitrogen stream giving 
clear honey which was diluted with buffer A (1300 μL). The 
resulting solution was centrifuged (4500 rpm, 5 min) and purified 
using 5% to 100% of buffer B in buffer A. Scaffold derivative 
30·2TFA (6.3 mg, 64.3%) was obtained as a white fluffy solid 
after lyophilization. tR = 24.9 min and 25.1 min 
(diastereoisomers). LCMS-ESI: average mass calcd [M+2H]2+: 
965.7; found: 965.5. 
CTV Scaffold derivative (31) Scaffold derivative 30·2TFA (6.0 
mg, 2.78 μmol), cyclic peptide 27 (4.3 mg, 3.06 μmol), TBTA 
(0.4 mg, 0.83 μmol) were placed into a flask and degassed DMF 
(415 μL) was added and the mixture was stirred under nitrogen 
atmosphere until clear solution was obtained. Next, degassed 
i-PrOH (555 μL), deionized H2O (125 μL) were added followed 
by the addition of 0.2M aqueous sodium ascorbate (8.4 μL, 
1.67 μmol) and 0.12M aqueous CuSO4 (7.0 μL, 0.83 μmol). The 
reaction mixture was stirred under nitrogen atmosphere and 
monitored by analytical HPLC which showed complete 
conversion after 19 h. Then, the solvents were removed with 
nitrogen stream giving red thick solid which was diluted with 
buffer B (50 μL) and buffer A (470 μL). The resulting solution 
was centrifuged (4500 rpm, 5 min) and purified using 5% to 90% 
of buffer B in buffer A. Scaffold derivative 31·3TFA (4.0 mg, 
40.4%) was obtained as a white fluffy solid after lyophilization. 
tR = 21.7 min. LCMS-ESI: average mass calcd [M+3H]
3+: 
1072.6; found: 1072.4. 
CTV Scaffold derivative (32) To a solution of scaffold 
derivative 31·3TFA (3.8 mg, 1.07 μmol) in degassed DMF (430 
μL) TBAF·3H2O (3.4 mg, 10.70 μmol) was added and the 
reaction mixture was stirred under nitrogen atmosphere and 
monitored by analytical HPLC which showed complete 
conversion after 17.5 h. Then, DMF was removed with nitrogen 
stream giving clear solid which was diluted with buffer A (515 
μL). The resulting solution was centrifuged (4500 rpm, 5 min) 
and purified using 5% to 80% of buffer B in buffer A. Scaffold 
derivative 32·3TFA (1.5 mg, 41.7%) was obtained as a white 
fluffy solid after lyophilization. tR = 18.1 min. LCMS-ESI: 
average mass calcd [M+3H]3+: 1020.5; found: 1020.3. 
Synthetic antibody mimic (33) CTV Scaffold derivative 
32·3TFA (1.4 mg, 0.41 μmol), cyclic peptide 29 (0.7 mg, 
0.45 μmol), TBTA (0.1 mg, 0.25 μmol) were placed into a flask 
and degassed DMF (130 μL) was added and the mixture was 
stirred under nitrogen atmosphere until clear solution was 
obtained. Next, degassed i-PrOH (60 μL), deionized H2O (15 μL) 
were added followed by the addition of 0.2M aqueous sodium 
ascorbate (2.5 μL, 0.49 μmol) and 0.12M aqueous CuSO4 (2.1 
μL, 0.25 μmol). The reaction mixture was stirred under nitrogen 
atmosphere and monitored by analytical HPLC which showed 
complete conversion after 89 h. Then, the solvents were removed 
with nitrogen stream giving red solid which was diluted with 
buffer B (50 μL) and buffer A (460 μL). The resulting solution 
was centrifuged (4500 rpm, 5 min) and purified using 5% to 80% 
of buffer B in buffer A. Synthetic antibody 33·5TFA (0.8 mg, 
40.0%) was obtained as a white fluffy solid after lyophilization. 
tR = 16.9 min. LCMS-ESI: average mass calcd [M+3H]
3+: 
1472.3; found: 1472.1. 
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